Review
Immunology
Vincent Dussupt, Kayvon Modjarrad, Shelly J. Krebs
Summary: The unprecedented Zika outbreak in the Americas from 2015-2016 led to global concern and accelerated the deployment of vaccine and therapeutic countermeasures. Several potent neutralizing antibodies against Zika and related flaviviruses have been discovered in recent years. Structure-based approaches have helped identify species-specific and cross-protective epitopes with therapeutic value.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Debbie Ching Ping Lee, Rahul Raman, Nahdiyah Abdul Ghafar, Yadunanda Budigi
Summary: This antibody-engineering platform utilizes amino acid networks to optimize framework regions and complementarity determining regions for engineering new antibodies with desired structure-function relationships. Test antibodies derived from different combinations of framework regions and complementarity determining regions show diverse functional readouts, despite high overall sequence similarity. The platform's approach effectively addresses important structural nuances of the framework region-complementarity determining region relationship that might be missed by traditional one dimensional sequence similarity-based analyses of antibodies.
ANTIVIRAL RESEARCH
(2021)
Review
Immunology
Charles D. Murin, Pavlo Gilchuk, James E. Crowe, Andrew B. Ward
Summary: This review describes how structural biology has revealed the molecular basis of broad ebolavirus neutralization, and discusses the history of monoclonal antibody therapeutics for ebolaviruses, as well as key structural studies that have advanced our understanding of ebolavirus glycoprotein structures and antibody-mediated neutralization.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Wen Jiang, Zherui Zhang, Yuhe Zhu, Ben Chen, Chunying Gu, Zhiyan Liu, Xukai Zhang, Hualong Xiong, Yanan Zhang, Bin Zheng, Rongjuan Wang, Shasha Jiao, An Wang, Tianying Zhang, Jinchao Zhang, Shuang Wang, Bo Zhang, Gang Li, Xun Gui
Summary: This study comprehensively characterized the breadth and efficacy of a fully human monoclonal antibody MW3321 targeting SARS-CoV-2. MW3321 retained full neutralization activity against all tested variants and showed resistance to escape mutation compared to another clinical-stage antibody. In animal models, MW3321 effectively reduced viral burden through viral neutralization and effector functions.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Chiranjib Chakraborty
Summary: Ebola virus disease is a deadly pathogenic disease caused by the Ebola virus, with scientists focusing on various therapeutic developments. Two monoclonal antibodies have shown efficacy in clinical trials and received approval, but there is a need for further development of more cost-effective therapies.
CURRENT OPINION IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Yuko Abe, Yasuhiko Suga, Kiyoharu Fukushima, Hayase Ohata, Takayuki Niitsu, Hiroshi Nabeshima, Yasuharu Nagahama, Hiroshi Kida, Atsushi Kumanogoh
Summary: Asthma is a disease characterized by airway inflammation, airway hyperresponsiveness, and airway remodeling. Current antibody therapeutics and biomarkers for asthma treatment are not satisfactory, and an ideal phenotype classification is needed to predict the response to antibody treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Florian Heinkel, Meghan M. Verstraete, Siran Cao, Janessa Li, Patrick Farber, Elizabeth Stangle, Begonia Silva-Moreno, Fangni Peng, Surjit Dixit, Martin J. Boulanger, Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera
Summary: The newly developed heterodimeric IgA Fc platform allows for the development of novel, multifunctional, and multimeric molecules that have the potential to transform the next generation of antibody therapeutics.
Article
Immunology
Sai Pooja Mahajan, Jeffrey A. Ruffolo, Rahel Frick, Jeffrey J. Gray
Summary: Antibodies are important therapeutics for treating cancer, infectious disease, and inflammation, and their target affinity needs to be improved through engineering. This study proposes the F(v)Hallucinator pipeline based on deep learning to design antibody sequences, resulting in the generation of inexpensive, diverse, and targeted antibody libraries enriched in binders for the target antigen. This provides a new approach for antibody affinity maturation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Microbiology
Halie M. Rando, Nils Wellhausen, Soumita Ghosh, Alexandra J. Lee, Anna Ada Dattoli, Fengling Hu, James Brian Byrd, Diane N. Rafizadeh, Ronan Lordan, Yanjun Qi, Yuchen Sun, Christian Brueffer, Jeffrey M. Field, Marouen Ben Guebila, Nafisa M. Jadavji, Ashwin N. Skelly, Bharath Ramsundar, Jinhui Wang, Rishi Raj Goel, Yoson Park, Simina M. Boca, Anthony Gitter, Casey S. Greene
Summary: The novel coronavirus SARS-CoV-2 poses a significant global threat after emerging in China in late 2019. Previous research on SARS and MERS has been valuable in identifying approaches to treating and preventing COVID-19. The medical and scientific communities have rapidly responded to the COVID-19 crisis and identified numerous candidate therapeutics.
Review
Chemistry, Multidisciplinary
Yu Chen, Ira Tandon, William Heelan, Yixin Wang, Weiping Tang, Quanyin Hu
Summary: Proteolysis Targeting Chimeras (PROTACs) have the potential to revolutionize the healthcare industry by degrading target proteins. However, inadequate delivery to the target site is one of the main challenges for PROTACs. The integration of PROTACs and delivery systems is being explored to enhance their in vivo performance.
CHEMICAL SOCIETY REVIEWS
(2022)
Review
Chemistry, Multidisciplinary
Xinjian Ji, Alexander L. Nielsen, Christian Heinis
Summary: Cyclic peptides are a class of molecules widely found in nature and used in drug development. Advances in synthesis and drug development have led to the creation of many cyclic peptide drugs. Cyclic peptides possess favorable properties that make them attractive for drug development. Currently, there are over 40 cyclic peptide drugs in use, and new technological advances suggest that this number could rapidly increase.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2023)
Article
Oncology
Laura M. Spring, Erika Nakajima, Jennifer Hutchinson, Elene Viscosi, Gayle Blouin, Colin Weekes, Hope Rugo, Beverly Moy, Aditya Bardia
Summary: Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan has shown promising therapeutic activity and received accelerated approval for the treatment of these patients. Limited information is available regarding adverse event management with this agent.
Article
Oncology
Koichi Nakamura, Kunihiro Asanuma, Takayuki Okamoto, Keisuke Yoshida, Yumi Matsuyama, Kouji Kita, Tomohito Hagi, Tomoki Nakamura, Akihiro Sudo
Summary: This study identified GPR64 as a potential therapeutic target for Ewing sarcoma and developed anti-GPR64 antibodies for sarcoma treatment. GPR64 was found to be widely expressed in various sarcomas, making it a promising target for antibody-based therapies.
Review
Pharmacology & Pharmacy
Ying Tian, Tao Zhang, Jing Li, Yong Tao
Summary: This article reviews the applications of exosomes in treating ophthalmic diseases. Exosomes, as delivery vectors, can effectively deliver drugs and therapeutic genes and avoid unnecessary immune responses. However, exosome-based therapies also come with potential ocular risks.
ADVANCED DRUG DELIVERY REVIEWS
(2023)
Article
Chemistry, Multidisciplinary
Ji-Hyun Yeom, Eunkyoung Shin, Hanyong Jin, Haifeng Liu, Yongyang Luo, Youngwoo Nam, Minkyung Ryu, Wooseok Song, Heeyoun Chi, Jeongkyu Kim, Kangseok Lee, Jeehyeon Bae
Summary: Antibodies are increasingly used for therapeutic purposes due to their remarkable specificity and affinity. However, current antibody therapies are limited to targeting proteins on the cell membrane or in extracellular fluids. This study presents a versatile intracellular antibody delivery system based on gold nanoparticles conjugated with DNA aptamers. The system enables efficient cytosolic delivery of antibodies to clinically important mutant proteins, showing promising results in reducing tumor cell viability and inducing apoptosis in mice. The findings suggest that this AuNPAptIgG-Ab system is a potential platform for effective intracellular antibody delivery.
JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
(2023)
Article
Medicine, Research & Experimental
Paul W. H. I. Parren, Dennis R. Burton, Andrew Bradbury, James S. Huston, Paul J. Carter, Trudi Veldman, Kerry A. Chester, James W. Larrick, Mark R. Alfenito, Jamie K. Scott, Louis M. Weiner, Gregory P. Adams, Janice M. Reichert
Article
Medicine, Research & Experimental
Janice M. Reichert
Article
Medicine, Research & Experimental
James W. Larrick, Mark R. Alfenito, Jamie K. Scott, Paul W. H. I. Parren, Dennis R. Burton, Andrew R. M. Bradbury, Cynthia A. Lemere, Anne Messer, James S. Huston, Paul J. Carter, Trudi Veldman, Kerry A. Chester, Janine Schuurman, Gregory P. Adams, Janice M. Reichert
Article
Medicine, Research & Experimental
Janice M. Reichert
Article
Medicine, Research & Experimental
Matthias Pauthner, Jenny Yeung, Chris Ullman, Joost Bakker, Thierry Wurch, Janice M. Reichert, Fridtjof Lund-Johansen, Andrew R. M. Bradbury, Paul J. Carter, Joost P. M. Melis
Article
Medicine, Research & Experimental
Guillaume Desoubeaux, Janice M. Reichert, Matthew Sleeman, Karen L. Reckamp, Bernhard Ryffel, Joerg P. Adamczewski, Theresa D. Sweeney, Rita Vanbever, Patrice Diot, Caroline A. Owen, Clive Page, Stephanie Lerondel, Alain Le Pape, Nathalie Heuze-Vourc'h
Article
Medicine, Research & Experimental
Janice M. Reichert
Editorial Material
Medicine, Research & Experimental
Janice M. Reichert
Article
Medicine, Research & Experimental
Helene Kaplon, Janice M. Reichert
Review
Biotechnology & Applied Microbiology
Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert, Paul W. H. I. Parren
NATURE REVIEWS DRUG DISCOVERY
(2019)
Article
Medicine, Research & Experimental
Helene Kaplon, Mrinalini Muralidharan, Zita Schneider, Janice M. Reichert
Article
Medicine, Research & Experimental
Helene Kaplon, Janice M. Reichert
Summary: The year 2020 saw significant developments in the field of antibody therapeutics, particularly in response to the COVID-19 pandemic. Several antibody products were granted emergency use authorization, and new antibody treatments received first approvals in the US or EU.
Article
Medicine, Research & Experimental
Helene Kaplon, Alicia Chenoweth, Silvia Crescioli, Janice M. Reichert
Summary: This article provides a summary of key events in the development of commercial antibody therapeutics in 2021 and a glimpse into potential events in 2022. The regulatory review process for antibody therapeutics targeting the SARS-CoV-2 coronavirus has been expedited, leading to emergency use authorizations and full approvals in multiple countries. Additionally, the late-stage commercial clinical pipeline for antibody therapeutics, excluding those for COVID-19, has seen significant growth over the past year.
Article
Medicine, Research & Experimental
Helene Kaplon, Silvia Crescioli, Alicia Chenoweth, Jyothsna Visweswaraiah, Janice M. Reichert
Summary: In this article, the key events in the development of commercial monoclonal antibody therapeutics in 2022 are discussed, and events that may occur in 2023 are forecasted. By mid-November, 12 antibody therapeutics had received first approvals in the United States or European Union, and an additional 7 had been approved in China or Japan. Globally, at least 24 investigational antibody therapeutics are undergoing regulatory review. The data show that, excluding antibodies for COVID-19, the late-stage commercial clinical pipeline has grown by approximately 20% in the past year.
Review
Biotechnology & Applied Microbiology
Charles Dumontet, Janice M. M. Reichert, Peter D. D. Senter, John M. M. Lambert, Alain Beck
Summary: Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic agents. The technology to develop these agents has improved in past years, but toxicity remains a key issue. This Review provides a broad overview of the recent advances and challenges in ADC development for cancer treatment.
NATURE REVIEWS DRUG DISCOVERY
(2023)
